Related Experiment Video
Updated: Sep 11, 2025
Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
Ultra-sensitive urinary lipoarabinomannan (LAM) immunoassay for tuberculosis detection: a performance evaluation
Qisheng Jiang1, Carolyn Duncan1, Harisha Ramachandraiah2
1Brightest Bio, St. Louis, MO, 63114, United States.
Background:
The development of rapid non-sputum tests remains a global priority to accelerate Tuberculosis (TB) diagnosis and treatment initiation. The only WHO-recommended rapid diagnostic test (RDT), the Alere Determine TB Lipoarabinomannan Ag (AlereLAM) has suboptimal sensitivity. A laboratory-based electrochemiluminescence LAM assay (EclLAM) is the current sensitivity benchmark for RDT development and the gold standard for urinary LAM detection. We assessed the diagnostic accuracy of an ultra-sensitive, Plasmonic Fluor-linked Immunosorbent LAM assay (PFLISA-LAM) compared to Sputum Xpert MTB/RIF, sputum culture and urine EclLAM.
Methods:
We developed and evaluated the assay performance of PFLISA-LAM. Two sub-studies were conducted using banked urine samples: 1. Preclinical study using 337 well-characterised urine samples for cutoff determination and initial evaluation of the performance of PFLISA-LAM compared to sputum Xpert MTB/RIF and culture. 2. A Diagnostic accuracy assessment study using 77 blinded samples to evaluate the performance of PFLISA-LAM compared to EclLAM versus microbiological reference standard (MRS, Xpert positive and/or culture positive).
Findings:
PFLISA-LAM has a limit of detection (LOD) of 0.84 ± 0.9 pg/mL when detecting purified LAM spiked in urine. In the preclinical study, the optimal assay cutoff was determined to be 1.7 pg/mL. The sensitivities of PFLISA-LAM and sputum Xpert MTB/RIF compared to culture were 51% (95% confidence interval [CI]: 43%-59%) and 62% (95% CI: 53%-70%). The specificities of PFLISA-LAM and Xpert MTB/RIF were 99% (95% CI: 96%-100%) and 100% (95% CI: 100%-100%). Combining PFLISA-LAM and Xpert MTB/RIF test data, an improved sensitivity of 76% (95% CI: 69%-83%) can be achieved. In the diagnostic study, the sensitivities of EclLAM and PFLISA-LAM assays were 42% (95% CI: 27%-59%) and 73% (95% CI: 56%-85%). The specificities of EclLAM and PFLISA-LAM were 95% (95% CI: 85%-99%) and 98% (95% CI: 88%-100%).
Interpretation:
With better analytical and diagnostic sensitivity compared to EclLAM, PFLISA-LAM can better detect urinary LAM in TB-positive cases. PFLISA-LAM assay also demonstrated the capability to increase the diagnostic value in detecting urinary LAM, complementing molecular tests, achieving improved diagnostic outcome.
Funding:
We report no external financial support for conducting the study.
